TransEnterix

RESEARCH TRIANGLE PARK, N.C. – David N. Gill has been named chief financial officer at TransEnterix.

Gill brings a wealth of medical device industry and international business experience to his role. During his career, Gill has led three initial public offerings and raised more than $500 million in equity capital.

In his current role, Gill managed TransEnterix’s recent $55-million Series B financing, which will be used by the company to manufacture and market its revolutionary SPIDER™ Surgical System this year.

Todd M. Pope, president and CEO, said that Gill’s financial acumen and industry knowledge has been critical as the company successfully raised needed capital.

“As we prepare to take our SPIDER™ Surgical System to market, David’s understanding of medical device industry issues and prudent financial management will allow our company to achieve the strategic fiscal goals we’ve set for ourselves,” Pope said.

Prior to joining TransEnterix, Gill served at different times as the chief financial officer of NxStage Medical Inc., CTI Molecular Imaging Inc. and Novoste Corp. All three companies were publicly traded medical device companies during Gill’s tenure. CTI Molecular Imaging later was acquired by Siemens Medical Solutions USA Inc. for $1 billion.

Gill serves as a director for Calypso Medical Technologies Inc. and for INC Research Inc., and is a member of the board of visitors at the Wake Forest University School of Divinity. He earned a bachelor’s degree with honors in accounting from Wake Forest University and a master’s degree with honors in business administration from Emory University.

An emerging medical device company headquartered in North Carolina, TransEnterix has secured an aggregate of $75 million in venture capital funding since its inception. The company plans a limited release of its SPIDER™ Surgical System in the next few months.

TransEnterix partners with the world’s leading surgeons to develop pioneering technologies that revolutionize minimally invasive surgery. It relies on rapid prototyping, intense pre-clinical labs and hands-on collaboration to accelerate learning and bring new medical devices to market more quickly.

To learn more about TransEnterix, visit www.transenterix.com. To learn more about the SPIDER™ Surgical System and to see how it works, visit www.spidersurgery.com.